CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
Saved in:
| Title: | CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. |
|---|---|
| Authors: | Ji, Danyang1 (AUTHOR), Luo, Yang1 (AUTHOR), Wang, Jiayu1 (AUTHOR), Chen, Shanshan1 (AUTHOR), Lan, Bo1 (AUTHOR), Ma, Fei1 (AUTHOR), Xu, Binghe1 (AUTHOR) xubinghe@medmail.com.cn, Fan, Ying1 (AUTHOR) fanyingfy@medmail.com.cn |
| Source: | BMC Cancer. 8/29/2023, Vol. 23 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
